Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA7 | P43166 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | XDH | P47989 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27980095 | 0.84 | CYP3A4 (0.51) | CYP3A4ACHECYP1A2CA12CA1 | |
| SCHEMBL143838 | 0.82 | CYP3A4 (0.46) | CYP3A4ACHECYP1A2CA12CA1 | |
| SCHEMBL1328619 | 0.78 | CYP3A4 (0.42) | CYP3A4ACHECYP1A2CA12CA1 | |
| SCHEMBL1658709 | 0.76 | ALDH1A1 (0.42) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL13743871 | 0.73 | KDM4E (0.71) | CYP3A4ACHECYP1A2CA12CA1 | |
| SCHEMBL725269 | 0.71 | CYP3A4 (0.77) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL1636307 | 0.70 | CYP3A4 (0.62) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL30550305 | 0.69 | FFAR1 (0.75) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL6493747 | 0.68 | CYP3A4 (0.79) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL6492470 | 0.68 | CA12 (0.59) | CYP3A4ACHECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| EP-2306828-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxosmithkline LLC (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009158315-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | CYP3A4 1174/4885ACHE 4880/4885CYP1A2 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.